NextCell Pharma AB (NXTCL.ST)
SEK 2.42
(-13.57%)
SEK 2.42
(-13.57%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -43.74 Million SEK | -4844.22% |
| 2023 | -884.83 Thousand SEK | 96.03% |
| 2022 | -22.26 Million SEK | -53.23% |
| 2021 | -14.52 Million SEK | -40.05% |
| 2020 | -10.37 Million SEK | 25.96% |
| 2019 | -14.01 Million SEK | -71.41% |
| 2018 | -8.17 Million SEK | -205.73% |
| 2017 | -2.67 Million SEK | 47.2% |
| 2016 | -5.06 Million SEK | -0.43% |
| 2015 | -5.04 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | -13.63 Million SEK | -50.94% |
| 2024 Q1 | 1.57 Million SEK | 1301.1% |
| 2024 Q2 | -422.74 Thousand SEK | -126.77% |
| 2024 Q3 | -9.03 Million SEK | -2036.5% |
| 2023 Q3 | 229.51 Thousand SEK | 120.6% |
| 2023 Q1 | -112.94 Thousand SEK | 97.86% |
| 2023 FY | -884.83 Thousand SEK | 96.03% |
| 2023 Q4 | 112.72 Thousand SEK | -50.89% |
| 2023 Q2 | -1.11 Million SEK | -886.43% |
| 2022 Q3 | -5.7 Million SEK | 23.45% |
| 2022 Q1 | -3.83 Million SEK | -41.99% |
| 2022 Q2 | -7.44 Million SEK | -94.33% |
| 2022 Q4 | -5.27 Million SEK | 7.42% |
| 2022 FY | -22.26 Million SEK | -53.23% |
| 2021 Q3 | -3.52 Million SEK | 29.99% |
| 2021 FY | -14.52 Million SEK | -40.05% |
| 2021 Q1 | -3.16 Million SEK | 3.74% |
| 2021 Q2 | -5.03 Million SEK | -59.37% |
| 2021 Q4 | -2.69 Million SEK | 23.47% |
| 2020 Q4 | -3.28 Million SEK | -14.16% |
| 2020 Q3 | -2.87 Million SEK | -30.36% |
| 2020 Q2 | -2.2 Million SEK | -21.09% |
| 2020 Q1 | -1.82 Million SEK | 71.06% |
| 2020 FY | -10.37 Million SEK | 25.96% |
| 2019 Q1 | -3.34 Million SEK | -115.41% |
| 2019 FY | -14.01 Million SEK | -71.41% |
| 2019 Q3 | -2.8 Million SEK | -73.73% |
| 2019 Q4 | -6.29 Million SEK | -124.61% |
| 2019 Q2 | -1.61 Million SEK | 51.77% |
| 2018 Q4 | -1.55 Million SEK | -0.39% |
| 2018 FY | -8.17 Million SEK | -205.73% |
| 2018 Q1 | -558.54 Thousand SEK | 73.53% |
| 2018 Q2 | -1.85 Million SEK | -232.48% |
| 2018 Q3 | -1.54 Million SEK | 16.68% |
| 2017 Q4 | -2.11 Million SEK | -1556.91% |
| 2017 Q1 | -166.07 Thousand SEK | 96.69% |
| 2017 Q2 | -269.61 Thousand SEK | -62.34% |
| 2017 Q3 | -127.36 Thousand SEK | 52.76% |
| 2017 FY | -2.67 Million SEK | 47.2% |
| 2016 Q1 | -95.98 Thousand SEK | 0.0% |
| 2016 FY | -5.06 Million SEK | -0.43% |
| 2016 Q4 | -5.01 Million SEK | -3605.76% |
| 2016 Q3 | 143.02 Thousand SEK | 249.0% |
| 2016 Q2 | -95.98 Thousand SEK | 0.0% |
| 2015 FY | -5.04 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 72.774% |
| Ziccum AB (publ) | -23.28 Million SEK | -87.873% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 112.632% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 204.693% |
| Mendus AB (publ) | 28.48 Million SEK | 253.572% |
| Genovis AB (publ.) | 54 Million SEK | 181.014% |
| Intervacc AB (publ) | -13.79 Million SEK | -217.153% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 2115.115% |
| Active Biotech AB (publ) | -1.67 Million SEK | -2511.829% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 539.106% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 263.112% |
| Aptahem AB (publ) | 2.63 Million SEK | 1763.018% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -1178.811% |
| Kancera AB (publ) | -1.96 Million SEK | -2126.368% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 56915.765% |
| Fluicell AB (publ) | 1.73 Million SEK | 2617.154% |
| Saniona AB (publ) | 11.78 Million SEK | 471.345% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -754.957% |
| Biovica International AB (publ) | 6.87 Million SEK | 736.152% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -87.897% |
| AcouSort AB (publ) | 8.38 Million SEK | 621.494% |
| Xintela AB (publ) | 78 Thousand SEK | 56187.358% |
| Abliva AB (publ) | -35.66 Million SEK | -22.671% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 70.219% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 1658.537% |
| OncoZenge AB (publ) | 3000.00 SEK | 1458371.3% |
| Amniotics AB (publ) | -1.93 Million SEK | -2166.743% |
| 2cureX AB (publ) | -37.48 Million SEK | -16.702% |
| CombiGene AB (publ) | -21.29 Million SEK | -105.48% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -10242.35% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 103.872% |
| Camurus AB (publ) | 1.58 Billion SEK | 102.768% |
| Corline Biomedical AB | 28.38 Million SEK | 254.151% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 64.355% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -27.119% |
| I-Tech AB | 27.56 Million SEK | 258.703% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 161.66% |
| Cyxone AB (publ) | 2.61 Million SEK | 1775.532% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 1385.576% |
| Biosergen AB | -456 Thousand SEK | -9493.89% |
| Cantargia AB (publ) | -3.45 Million SEK | -1167.695% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -375.834% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 489.972% |
| Nanologica AB (publ) | -76 Thousand SEK | -57463.341% |
| SynAct Pharma AB | -778 Thousand SEK | -5523.154% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -22567.43% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -238.555% |
| Lipum AB (publ) | 53 Thousand SEK | 82643.658% |
| BioInvent International AB (publ) | 71.46 Million SEK | 161.22% |
| Alzinova AB (publ) | 19.87 Million SEK | 320.127% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 220.522% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 3090.263% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -291554.26% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 2738.609% |
| Simris Alg AB (publ) | 2 Million SEK | 2279.778% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -1122.015% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 223.624% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -4070.461% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 1496.366% |